What are the criteria and recommended guidelines for initiating pharmacologic therapy in type 2 diabetes, including indications, first‑line agent selection, dosing, renal function considerations, and alternative medication options?

When to Start Diabetes Medications in Type 2 Diabetes

Start pharmacologic therapy immediately at diagnosis with metformin plus lifestyle modifications for all patients with type 2 diabetes unless contraindicated. 1, 2

Immediate Initiation Criteria

Start Insulin Immediately (with or without other agents) if:

• A1C ≥10% (86 mmol/mol) 3, 4
• Blood glucose ≥300 mg/dL (16.7 mmol/L) 3, 4
• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) 3, 4
• Evidence of ongoing catabolism (unintentional weight loss) 3, 4

Start Dual Therapy at Diagnosis if:

• A1C >7.5% at diagnosis - begin metformin PLUS a second agent immediately 5
• A1C ≥1.5% above individualized target - consider dual therapy to shorten time to goal 3, 1

First-Line Agent Selection Algorithm

Step 1: Assess for Cardiovascular/Renal Comorbidities

If patient has ANY of the following, prioritize organ protection OVER glycemic control:

Heart Failure (HF) Present:

• Start SGLT2 inhibitor (regardless of A1C or ejection fraction) 1, 6
• This is for both glycemic management AND prevention of HF hospitalizations
• Works for both reduced and preserved ejection fraction

Chronic Kidney Disease (CKD) Present:

• eGFR 20-60 mL/min/1.73 m² and/or albuminuria:

  • First choice: SGLT2 inhibitor 1, 6
  • Alternative: GLP-1 RA with demonstrated CKD benefit
  • Note: Glycemic benefits of SGLT2i reduced at eGFR <45 1, 6

• eGFR <30 mL/min/1.73 m² (advanced CKD):

  • Prefer GLP-1 RA (lower hypoglycemia risk, cardiovascular benefit) 1, 6

Established Atherosclerotic Cardiovascular Disease (ASCVD):

• Add SGLT2 inhibitor OR GLP-1 RA with proven cardiovascular benefit 2, 4
• SGLT2i reduces: all-cause mortality, MACE, CKD progression, CHF hospitalization 2
• GLP-1 RA reduces: all-cause mortality, MACE, stroke 2

Step 2: If No Cardiovascular/Renal Disease

Start metformin (unless contraindicated) 1, 3, 2, 7

Then select second agent based on:

If Weight Loss is Priority:

• GLP-1 RA (>5% weight loss, may exceed 10%) 8
• Dual GIP/GLP-1 RA (tirzepatide - greater weight loss) 6, 8
• SGLT2i (modest weight loss) 1

If Metabolic Liver Disease (MASLD/MASH):

• GLP-1 RA or dual GIP/GLP-1 RA 6
• Alternative: Pioglitazone (if biopsy-proven MASH or high fibrosis risk) 6

If Cost is Major Barrier:

• Sulfonylureas or thiazolidinediones may be considered 5
• However, these are inferior for mortality/morbidity reduction 2
• Do NOT use DPP-4 inhibitors - no mortality/morbidity benefit 2

Renal Function Considerations

Metformin Dosing by eGFR:

• eGFR ≥30 mL/min/1.73 m²: Safe to use 3, 7
• eGFR <30 mL/min/1.73 m²: Contraindicated 3

SGLT2 Inhibitor Considerations:

• Can use down to eGFR 20 mL/min/1.73 m² for cardio-renal protection 1, 6
• Glycemic efficacy diminishes below eGFR 45 1, 6

Target A1C Goals

• Most adults: 7-8% 2
• Deintensify if A1C <6.5% (risk of hypoglycemia outweighs benefit) 2
• Individualize based on: hypoglycemia risk, life expectancy, complications, comorbidities 2

Critical Pitfalls to Avoid

1. Do NOT delay treatment - clinical inertia worsens outcomes 4, 9
2. Do NOT use stepwise monotherapy approach in patients with A1C >7.5% - start combination therapy 1, 5
3. Do NOT prioritize glycemic control over organ protection in patients with HF/CKD/ASCVD 1, 6
4. Do NOT add DPP-4 inhibitors - they provide no mortality/morbidity benefit 2
5. Monitor vitamin B12 on metformin (especially with anemia/neuropathy) 3, 7
6. Reduce/discontinue sulfonylureas or long-acting insulin when adding SGLT2i or GLP-1 RA to prevent severe hypoglycemia 2

Medication Reassessment

Reevaluate every 3-6 months and adjust based on: 1, 4

• A1C achievement
• Weight goals
• Medication tolerance
• Adherence
• Comorbidity changes